Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CA-170 in advanced tumors and lymphomas
NCT02812875Phase 1Completed
- Sponsor
- Curis, Inc.
- Start
- May 2016
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of AUPM-170 in solid tumor (advanced stage), lymphoma, mesothelioma and 10 more, sponsored by Curis, Inc. Primary endpoints: Dose-Limiting Toxicity at 24 months, Maximum Tolerated Dose at 24 months and 1 more. Started May 2016; status: completed.
02
Drugs
AUPM-170
03
Conditions
solid tumor (advanced stage)lymphomamesotheliomamelanomanon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02812875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02812875.